Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
International Journal of Cancer|January 9, 2004
Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancerNeil K Rushmere, Janice M Knowlden, Julia M W Gee, et al.
Biomechanics and Modeling in Mechanobiology|September 8, 2012
Measuring and modeling patient-specific distributions of material properties in abdominal aortic aneurysm wallC Reeps, A Maier, J Pelisek, et al.
Breast Cancer Research : BCR|March 15, 2011
Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1Iain R Hutcheson, Lindy Goddard, Denise Barrow, et al.
Breast Cancer Research and Treatment|November 2, 2005
Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growthD J Britton, I R Hutcheson, J M Knowlden, et al.
Endocrine-Related Cancer|January 30, 2007
Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapyIain R Hutcheson, Janice M Knowlden, Helen E Jones, et al.
Breast Cancer Research : BCR|September 1, 2018
Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cellsIain R Hutcheson, Janice M Knowlden, Steve E Hiscox, et al.
Breast Cancer Research : BCR|August 10, 2007
Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cellsIain R Hutcheson, Janice M Knowlden, Steve E Hiscox, et al.
Cellular and Molecular Life Sciences : CMLS|August 16, 2020
The ZIP6/ZIP10 heteromer is essential for the zinc-mediated trigger of mitosisThirayost Nimmanon, Silvia Ziliotto, Olivia Ogle, et al.
Breast Cancer Research : BCR|January 25, 2014
Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitroNicola J Jordan, Carol M Dutkowski, Denise Barrow, et al.
The Journal of Pathology|October 1, 2008
Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survivalJ M W Gee, J J Eloranta, J C Ibbitt, et al.
Pageof 7